Abstract P2-08-10: Validation of prediction of local recurrence (LR) by Prosigna® (PAM50) in a Danish breast cancer cooperative group (DBCG) cohort of hormone receptor positive (HR+), postmenopausal early breast cancer (EBC) patients allocated to 5yr of endocrine therapy (ET)

Jens Ole Eriksen; M-B Jensen; Anne-Vibeke Lænkholm; Bent Ejlertsen

Abstract P2-08-10: Validation of prediction of local recurrence (LR) by Prosigna® (PAM50) in a Danish breast cancer cooperative group (DBCG) cohort of hormone receptor positive (HR+), postmenopausal early breast cancer (EBC) patients allocated to 5yr of endocrine therapy (ET)

Jens Ole Eriksen
, M-B Jensen
, Anne-Vibeke Lænkholm
, Bent Ejlertsen

Originalsprog	Engelsk
Tidsskrift	Cancer Research
Vol/bind	76
Udgave nummer	4 supplement
Sider (fra-til)	p2-08-10
ISSN	0008-5472
Status	Udgivet - 2016

Citationsformater

Eriksen, J. O., Jensen, M.-B., Lænkholm, A.-V., & Ejlertsen, B. (2016). Abstract P2-08-10: Validation of prediction of local recurrence (LR) by Prosigna® (PAM50) in a Danish breast cancer cooperative group (DBCG) cohort of hormone receptor positive (HR+), postmenopausal early breast cancer (EBC) patients allocated to 5yr of endocrine therapy (ET). Cancer Research, 76(4 supplement), p2-08-10.

Abstract P2-08-10: Validation of prediction of local recurrence (LR) by Prosigna® (PAM50) in a Danish breast cancer cooperative group (DBCG) cohort of hormone receptor positive (HR+), postmenopausal early breast cancer (EBC) patients allocated to 5yr of endocrine therapy (ET). / Eriksen, Jens Ole; Jensen, M-B; Lænkholm, Anne-Vibeke et al.
I: Cancer Research, Bind 76, Nr. 4 supplement, 2016, s. p2-08-10.

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

Eriksen, JO, Jensen, M-B, Lænkholm, A-V & Ejlertsen, B 2016, 'Abstract P2-08-10: Validation of prediction of local recurrence (LR) by Prosigna® (PAM50) in a Danish breast cancer cooperative group (DBCG) cohort of hormone receptor positive (HR+), postmenopausal early breast cancer (EBC) patients allocated to 5yr of endocrine therapy (ET)', Cancer Research, bind 76, nr. 4 supplement, s. p2-08-10.

Eriksen JO, Jensen MB, Lænkholm AV , Ejlertsen B. Abstract P2-08-10: Validation of prediction of local recurrence (LR) by Prosigna® (PAM50) in a Danish breast cancer cooperative group (DBCG) cohort of hormone receptor positive (HR+), postmenopausal early breast cancer (EBC) patients allocated to 5yr of endocrine therapy (ET). Cancer Research. 2016;76(4 supplement):p2-08-10.

Eriksen, Jens Ole ; Jensen, M-B ; Lænkholm, Anne-Vibeke et al. / Abstract P2-08-10: Validation of prediction of local recurrence (LR) by Prosigna® (PAM50) in a Danish breast cancer cooperative group (DBCG) cohort of hormone receptor positive (HR+), postmenopausal early breast cancer (EBC) patients allocated to 5yr of endocrine therapy (ET). I: Cancer Research. 2016 ; Bind 76, Nr. 4 supplement. s. p2-08-10.

@article{6e1d975431044e9b9c1955d8273f6dc6,

title = "Abstract P2-08-10: Validation of prediction of local recurrence (LR) by Prosigna{\textregistered} (PAM50) in a Danish breast cancer cooperative group (DBCG) cohort of hormone receptor positive (HR+), postmenopausal early breast cancer (EBC) patients allocated to 5yr of endocrine therapy (ET)",

author = "Eriksen, \{Jens Ole\} and M-B Jensen and Anne-Vibeke L{\ae}nkholm and Bent Ejlertsen",

year = "2016",

language = "English",

volume = "76",

pages = "p2--08--10",

journal = "Cancer Research",

issn = "0008-5472",

publisher = "University of Chicago Press",

number = "4 supplement",

}

TY - ABST

T1 - Abstract P2-08-10: Validation of prediction of local recurrence (LR) by Prosigna® (PAM50) in a Danish breast cancer cooperative group (DBCG) cohort of hormone receptor positive (HR+), postmenopausal early breast cancer (EBC) patients allocated to 5yr of endocrine therapy (ET)

AU - Eriksen, Jens Ole

AU - Jensen, M-B

AU - Lænkholm, Anne-Vibeke

AU - Ejlertsen, Bent

PY - 2016

Y1 - 2016

M3 - Conference abstract in journal

SN - 0008-5472

VL - 76

SP - p2-08-10

JO - Cancer Research

JF - Cancer Research

IS - 4 supplement

ER -